title: The metabotropic glutamate receptor subtype 7 rs3792452 polymorphism is associated with the response to methylphenidate in children with attention-deficit/hyperactivity disorder.
abstract: OBJECTIVE
  The purpose of this study was to investigate the association between the metabotropic glutamate receptor subtype 7 (mGluR7) gene (GRM7) polymorphism and treatment response to methylphenidate in Korean children with attention-deficit/hyperactivity disorder (ADHD).
  
  
  METHODS
  We enrolled 175 medication-naïve children with ADHD in an open-label 8 week trial of methylphenidate. The participants were genotyped and evaluated using the Clinical Global Impressions (CGI) Scale and the parent version of the ADHD Rating Scale-IV (ADHD-RS) before and after treatment.
  
  
  RESULTS
  After the 8 week course of methylphenidate, children with the GRM7 rs37952452 polymorphism G/A genotype had a more pronounced response rate to the treatment than did children with the G/G genotype according to the ADHD-RS scores (72.2% vs. 55.4%, respectively; p=0.011) and the more stringent standard of combined ADHD-RS and CGI-Improvement (CGI-I) scores (50.0% vs. 35.3%, respectively; p=0.044).
  
  
  CONCLUSIONS
  The present study suggests that the GRM7 rs37952452 polymorphism may play a role in the treatment response to methylphenidate in children with ADHD. Further studies to evaluate the association between glutamate genes and treatment response to methylphenidate in children with ADHD, including a replication of our findings using a control or comparative group in a larger sample, are warranted.
authors.affiliation: 1 Division of Child and Adolescent Psychiatry, Department of Psychiatry, Seoul National University College of Medicine , Seoul, Republic of Korea.
authors.forename: Subin
authors.initials: S
authors.lastname: Park
authors.forename: Bung-Nyun
authors.initials: BN
authors.lastname: Kim
authors.forename: Soo-Churl
authors.initials: SC
authors.lastname: Cho
authors.forename: Jae-Won
authors.initials: JW
authors.lastname: Kim
authors.forename: Johanna Inhyang
authors.initials: JI
authors.lastname: Kim
authors.forename: Min-Sup
authors.initials: MS
authors.lastname: Shin
authors.forename: Hee-Jeong
authors.initials: HJ
authors.lastname: Yoo
authors.forename: Doug Hyun
authors.initials: DH
authors.lastname: Han
authors.forename: Jae Hoon
authors.initials: JH
authors.lastname: Cheong
mesh_terms: D000293:Adolescent; D044466:Asian People; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000235:genetics; D016022:Case-Control Studies; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D002648:Child; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use*; D020641:Polymorphism, Single Nucleotide; D011569:Psychiatric Status Rating Scales; D018094:Receptors, Metabotropic Glutamate / Q000235:genetics*; D056910:Republic of Korea; D016896:Treatment Outcome
chemical_list: D000697:Central Nervous System Stimulants; D018094:Receptors, Metabotropic Glutamate; C102719:metabotropic glutamate receptor 7; D008774:Methylphenidate